Juno Therapeutics Inc (NASDAQ:JUNO) shares are falling 4% after last week’s hit: the firm’s pivotal ROCKET trial of JCAR015, a product candidate in …
Exelixis, Inc. (NASDAQ:EXEL) just announced a clinical update from ongoing trials evaluating its pipeline drug Cotellic (cobimetinib), the biotech firm-created MEK inhibitor that …
On October 9th, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) presented a poster with accumulative updates from its Phase I/II trial results of investigational, targeted cancer …
Leerink top analyst Michael Schmidt provides insight on shares of Exelixis, Inc (NASDAQ:EXEL) after hosting the 2016 Leerink Partners Immuno-Oncology Roundtable Conference in …
In a research report released on Monday, Leerink top analyst Michael Schmidt initiated coverage on shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) with a price …
Leerink analyst Michael Schmidt provides a second-quarter recap for shares of Uniqure NV (NASDAQ:QURE), reiterating an Outperform rating with a $27 price target, …
On August 19th, Exelixis, Inc. (NASDAQ:EXEL) entered into additional, privately negotiated exchange agreements with certain holders of the company’s 4.
Leerink praises significant upside opportunities for Exelixis’ pipeline
Exelixis, Inc. (NASDAQ:EXEL) is set to release its second-quarter financial results after the markets close on Wednesday, August 3rd.
Analyst Michael Schmidt from Leerink Swann shared his thoughts on Juno Therapeutics Inc (NASDAQ:JUNO), following its $10 million acquisition of RedoxTherapies. In addition to …
